-+ 0.00%
-+ 0.00%
-+ 0.00%

Minerva Neurosciences Q4 2024 GAAP EPS $(0.56) Beats $(1.05) Estimate, Cash, Cash Equivalents And Restricted Cash At December 31, 2024, Were Approximately $21.5M

Benzinga·02/25/2025 12:14:18
Listen to the news
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(1.05) by 46.67 percent. This is a 52.94 percent increase over losses of $(1.19) per share from the same period last year.